XAIR — Beyond Air, Inc.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1641631 ·
Last close
$0.44
Market Cap
$5.55M
52W High
$0.97
52W Low
$0.38
ADV30
395,502
Next earnings
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 2,194,000 300,000 -6,596,000 -7,336,000 36,774,000 6,643,000 28,488,000
Sep 2025 1,818,000 -298,000 -7,661,000 -7,940,000 30,965,000 9,699,000 17,870,000
Jun 2025 1,760,000 156,000 -7,617,000 -7,691,000 28,114,000 4,976,000 17,706,000
Mar 2025 1,152,000 -32,000 -7,174,000 -8,034,000 30,062,000 4,665,000 15,721,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-20,155,000
Investing CF
$-646,000
Financing CF
$28,689,000
CapEx
$-1,976,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-5.43
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-309,289,000
Inventory
$1,761,000
Receivables
$1,259,000
ST Investments
$5,018,000
EBIT TTM
$-29,174,000
Pretax Income TTM
$-32,029,000
Interest Exp TTM
$2,855,000
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$6,924,000
EBITDA
$-25,785,000
Free Cash Flow
$-18,648,376
Enterprise Value
$16,327,267
Total Cash
$11,661,000
Total Debt
$23,591,000
Shares Out
12,692,684
Trailing EPS
$-4.47
Book Value
$0.96
ROE
-240.2%
ROA
-51.2%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Mar 2025 3,705,000 -44,537,000 -46,625,000 30,062,000 15,721,000 -38,218,000
Mar 2024 1,159,000 -63,007,000 -60,242,000 56,961,000 29,775,000 -56,014,000
Mar 2023 0 -52,059,000 -55,816,000 68,749,000 26,721,000 -33,009,000
Mar 2022 0 -30,210,000 -43,177,000 99,199,000 20,990,000 -23,134,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.66

Peers — same industry

TickerNameMarket CapLastDaily %
FEED ENvue Medical, Inc. $5.64M $0.93
ADMT ADM TRONICS UNLIMITED, INC. $5.41M $0.08
CLGN CollPlant Biotechnologies Ltd $5.98M $0.41
STME Stimcell Energetics Inc. $6.13M $0.29
HSCS HeartSciences Inc. $6.15M $1.93

News headlines (Yahoo Finance, 1h cache)

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026
2026-04-20 12:00 · Yahoo
Beyond Air to Participate in the D. Boral Capital Global Conference 2026
2026-04-15 12:00 · Yahoo
Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)
2026-04-01 13:00 · Yahoo
Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO
2026-03-26 20:05 · Yahoo
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial
2026-03-17 20:35 · Yahoo
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
2026-03-13 12:35 · Yahoo
Beyond Air to Participate in the 38th Annual Roth Conference in March
2026-03-11 11:00 · Yahoo
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
2026-03-10 14:21 · Yahoo
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.
2026-03-10 11:30 · Yahoo
Beyond Air Inc (XAIR) Expands Focus on Nitric Oxide Therapies
2026-03-04 10:39 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.